MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

  title={MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.},
  author={David H. Miller and Derek Tuck Loong Soon and Kryshani T.M. Fernando and David G. MacManus and Gareth J. Barker and Tarek Yousry and Elizabeth H. Fisher and P. W. O'Connor and J. Theodore Phillips and Chris H. Polman and Ludwig Kappos and Michael Hutchinson and Eva Kubala Havrdov{\'a} and Fred D. Lublin and Gavin Giovannoni and Andrzej Wajgt and Richard A. Rudick and Frances M. Lynn and Michael A. Panzara and Alfred W. Sandrock},
  volume={68 17},
BACKGROUND In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients with relapsing multiple sclerosis (MS), natalizumab significantly reduced the relapse rate by 68% and progression of sustained disability by 42% vs placebo. We report the effect of natalizumab on MRI measures from the AFFIRM study. METHODS The number and volume of gadolinium (Gd)-enhancing, new or enlarging T2-hyperintense, and… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 128 extracted citations

Quantification of blood-to-brain transfer rate in multiple sclerosis.

Multiple sclerosis and related disorders • 2013
View 11 Excerpts
Highly Influenced

Progressive multifocal leukoencephalopathy and natalizumab

Journal of Neurology • 2011
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…